 This study is a prospective, randomized, double-blind, placebo-controlled evaluation of the safety of a topically applied formulation of rapamycin to cutaneous fibromatous lesions in subjects with Tuberous Sclerosis Complex TSC and Neurofibromatosis I NF1. Subjects will apply either a Polyvinylidene fluoride PVDF coating Skincerity containing rapamycin or the PVDF coating alone nightly to fibromatous lesions for a duration of six months. 